Clinical Trial Pipeline Tracker

Research evidence excerpt

Clinical Trial Pipeline Tracker

UpdateMExhibit 11: Trials with decreased estimated patient recruitment

Primary Previous Est.

Company Drug Stage Event/Study title Status Est. Size Identifier

Completion Size

A Study to Assess Adverse Events, and How Intravenously (IV) Infused

Active, not

Abbvie ABBV-969 Phase1 ABBV-969 Moves Through the Bodies of Adult Participants With May-27 152 230 NCT06318273

recruiting

Metastatic Castration-Resistant Prostate Cancer

A Phase 1, Randomized, Double-blind, Placebo-controlled Study

Amgen AMG 691 Phase1 Evaluating AMG 691 in Healthy Participants and Participants With Apr-27 21 124 NCT06637371

Mild-to-Moderate Asthma

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and

Pharmacodynamics of Single- and Multiple-Ascending Doses and

BeOne Medicines BGB-45035 Phase1 Jun-26 Completed 203 211 NCT06342713

Food Effect of BGB-45035 in Healthy Participants and in Adults With

Autoimmune Dermatological Diseases

CLN-617 Alone and in Combination With Pembrolizumab in Patients

Cullinan CLN-617|Pembrolizumab Phase1 Jun-26 Terminated 23 86 NCT06035744

With Advanced Solid Tumors

Letrozole|Abemaciclib|LY3023414|Metfo RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in

Eli Lilly Phase2 Aug-28 Recruiting 110 180 NCT03675893

rmin|Gedatolisib Endometrial Cancer

Eli Lilly LY4005130|LY4005130 Phase1 A Study of LY4005130 in Healthy Participants Apr-26 Completed 110 118 NCT06690996

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Active, not

Gilead Lenacapavir Injection|Lenacapavir Tablet Phase3 Sep-28 339 350 NCT07047716

Prophylaxis (PrEP) recruiting

KVA12123 - Dose Escalation|KVA12123

Plus Pembrolizumab - Dose A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in